Zhilin Xiao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Zhilin Xiao has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Bolin Xiao
School of Stomatological, WuHan University, Wuhan, Hubei, China
2 shared publicationsGuo-Long Yu
2 shared publications- Li Fang
Deparment of Thoracic Surgery, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China
2 shared publications Mei Yang
Department of Geriatric Cardiology, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China
2 shared publicationsMei-Fang Chen
2 shared publicationsXiao-Bin Chen
2 shared publications
Latest Publications
- Open Access
- 3 November 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-11
The association between serum uric acid and homocysteine is mediated by metabolic risk factors
Previous studies have revealed a link between serum uric acid (SUA) and homocysteine (Hcy) levels, but it is unclear whether such relationship can be mediated by metabolic risk factors. This study evaluated the relationship between SUA and Hcy levels through a mediation analysis, examining the extent to which metabolic risk factors mediate this association. A total of 16,870 participants aged 20–60 years was consecutively enrolled at the Third Xiangya Hospital, Central South University. Data on health behaviours and medical history were collected through self-reported health questionnaires. Laboratory examinations were conducted by trained personnel via standardized methods. Logistic regression models were used to evaluate the associations between SUA and Hcy levels. Mediation analysis was conducted to explore the possible impact of metabolic risk factors on the SUA-Hcy relationship. There was a significant dose‒response relationship between higher SUA quartiles and increased hyperhomocysteinemia (HHcy) risk (P for trend < 0.01). Mediation analysis indicated that the relationship between SUA and HHcy was partially mediated by triglyceride (TG, 10.78%), diastolic blood pressure (DBP, 10.12%), systolic blood pressure (SBP, 7.63%), body mass index (BMI, 6.02%), and total cholesterol (TC, 0.56%); high-density lipoprotein cholesterol (HDL-C) negatively mediated this association, accounting for 13.03% of the effect. SUA is positively associated with HHcy risk and potentially mediated by metabolic factors such as HDL-C, TG, DBP, SBP, and BMI.
- 3 November 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-11
Open AccessThe association between serum uric acid and homocysteine is mediated by metabolic risk factors
Previous studies have revealed a link between serum uric acid (SUA) and homocysteine (Hcy) levels, but it is unclear whether such relationship can be mediated by metabolic risk factors. This study evaluated the relationship between SUA and Hcy levels through a mediation analysis, examining the extent to which metabolic risk factors mediate this association. A total of 16,870 participants aged 20–60 years was consecutively enrolled at the Third Xiangya Hospital, Central South University. Data on health behaviours and medical history were collected through self-reported health questionnaires. Laboratory examinations were conducted by trained personnel via standardized methods. Logistic regression models were used to evaluate the associations between SUA and Hcy levels. Mediation analysis was conducted to explore the possible impact of metabolic risk factors on the SUA-Hcy relationship. There was a significant dose‒response relationship between higher SUA quartiles and increased hyperhomocysteinemia (HHcy) risk (P for trend < 0.01). Mediation analysis indicated that the relationship between SUA and HHcy was partially mediated by triglyceride (TG, 10.78%), diastolic blood pressure (DBP, 10.12%), systolic blood pressure (SBP, 7.63%), body mass index (BMI, 6.02%), and total cholesterol (TC, 0.56%); high-density lipoprotein cholesterol (HDL-C) negatively mediated this association, accounting for 13.03% of the effect. SUA is positively associated with HHcy risk and potentially mediated by metabolic factors such as HDL-C, TG, DBP, SBP, and BMI.
- Open Access
- 24 March 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-10
The association between blood count based inflammatory markers and the risk of atrial fibrillation heart failure and cardiovascular mortality
The prevalence and progression of cardiovascular disease (CVD) are significantly influenced by low-grade chronic inflammation. Our aim was to investigate the association of blood-count-based inflammatory markers with atrial fibrillation (AF), heart failure (HF), and cardiovascular mortality. We utilized prospective follow-up data from the UK Biobank, including 334,674 individuals (aged between 39 and 70 years) free of HF and AF at baseline. The exposures were blood-count-based inflammatory markers, including neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), systemic immune-inflammation index (SII), aggregate index of systemic inflammation (AISI), and systemic inflammatory response index (SIRI), which were computed using leukocyte counts (lymphocytes, monocytes, and neutrophils). The primary outcomes were the occurrence of AF, HF and cardiovascular-related deaths. Cox proportional hazards models were employed to determine hazard ratios (HRs) and their 95% confidence intervals (CIs) for assessing the longitudinal association between inflammatory markers and the development of cardiovascular events. Survival analysis was illustrated using Kaplan–Meier curves with the occurrence of AF, HF and CVD mortality as the endpoint. There were 16,994 incidences of AF and 7342 incidences of HF over a median follow-up of 10.4 years (range, 2.4–12.1). Additionally, there were 3434 deaths from CVD causes. A higher risk of cardiovascular mortality was significantly associated with NLR, MLR, SIRI, AISI, and SII in multivariable adjusted models (HR 1.44, 95% CI 1.30–1.58; HR 1.46, 95% CI 1.31–1.61; HR 1.57, 95% CI 1.41–1.75; HR 1.57, 95% CI 1.41–1.73; and HR 1.36, 95% CI 1.24–1.49, respectively). Furthermore, our analysis revealed positive associations between NLR, MLR, SIRI, and AISI and the risk for AF (HR 1.18, 95% CI 1.13–1.24; HR 1.19, 95% CI 1.14–1.25; HR 1.22, 95% CI 1.16–1.27; and HR 1.08, 95% CI 1.03–1.13, respectively), and HF (HR 1.42, 95% CI 1.33–1.52; HR 1.28, 95% CI 1.19–1.37; HR 1.45, 95% CI 1.35–1.56; and HR 1.32, 95% CI 1.23–1.41, respectively). Furthermore, the SII demonstrated a positive association with HF (HR 1.24, 95% CI 1.16–1.32). However, the association with AF was not statistically significant (HR 1.01, 95% CI 0.97–1.06). In summary, our research provides preliminary evidence that blood cell indices associated with the systemic inflammatory response, may serve as potential biomarkers for the risk of developing AF, HF and CVD mortality. Additionally, it is likely that a systemic inflammatory-immune response existed before the clinical diagnosis. Identifying high-risk populations based on the levels of inflammatory markers could help reduce the risk of death and prevent the onset of AF and HF. Further investigation is warranted to determine whether reducing inflammatory markers causally improves cardiovascular outcomes.
- 24 March 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-10
Open AccessThe association between blood count based inflammatory markers and the risk of atrial fibrillation heart failure and cardiovascular mortality
The prevalence and progression of cardiovascular disease (CVD) are significantly influenced by low-grade chronic inflammation. Our aim was to investigate the association of blood-count-based inflammatory markers with atrial fibrillation (AF), heart failure (HF), and cardiovascular mortality. We utilized prospective follow-up data from the UK Biobank, including 334,674 individuals (aged between 39 and 70 years) free of HF and AF at baseline. The exposures were blood-count-based inflammatory markers, including neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), systemic immune-inflammation index (SII), aggregate index of systemic inflammation (AISI), and systemic inflammatory response index (SIRI), which were computed using leukocyte counts (lymphocytes, monocytes, and neutrophils). The primary outcomes were the occurrence of AF, HF and cardiovascular-related deaths. Cox proportional hazards models were employed to determine hazard ratios (HRs) and their 95% confidence intervals (CIs) for assessing the longitudinal association between inflammatory markers and the development of cardiovascular events. Survival analysis was illustrated using Kaplan–Meier curves with the occurrence of AF, HF and CVD mortality as the endpoint. There were 16,994 incidences of AF and 7342 incidences of HF over a median follow-up of 10.4 years (range, 2.4–12.1). Additionally, there were 3434 deaths from CVD causes. A higher risk of cardiovascular mortality was significantly associated with NLR, MLR, SIRI, AISI, and SII in multivariable adjusted models (HR 1.44, 95% CI 1.30–1.58; HR 1.46, 95% CI 1.31–1.61; HR 1.57, 95% CI 1.41–1.75; HR 1.57, 95% CI 1.41–1.73; and HR 1.36, 95% CI 1.24–1.49, respectively). Furthermore, our analysis revealed positive associations between NLR, MLR, SIRI, and AISI and the risk for AF (HR 1.18, 95% CI 1.13–1.24; HR 1.19, 95% CI 1.14–1.25; HR 1.22, 95% CI 1.16–1.27; and HR 1.08, 95% CI 1.03–1.13, respectively), and HF (HR 1.42, 95% CI 1.33–1.52; HR 1.28, 95% CI 1.19–1.37; HR 1.45, 95% CI 1.35–1.56; and HR 1.32, 95% CI 1.23–1.41, respectively). Furthermore, the SII demonstrated a positive association with HF (HR 1.24, 95% CI 1.16–1.32). However, the association with AF was not statistically significant (HR 1.01, 95% CI 0.97–1.06). In summary, our research provides preliminary evidence that blood cell indices associated with the systemic inflammatory response, may serve as potential biomarkers for the risk of developing AF, HF and CVD mortality. Additionally, it is likely that a systemic inflammatory-immune response existed before the clinical diagnosis. Identifying high-risk populations based on the levels of inflammatory markers could help reduce the risk of death and prevent the onset of AF and HF. Further investigation is warranted to determine whether reducing inflammatory markers causally improves cardiovascular outcomes.
- Open Access
- 1 March 2025
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 18, 3177-3200
Inflammatory Biomarkers in Coronary Artery Disease: Insights From Mendelian Randomization and Transcriptomics
Background: The identification of inflammatory genes linked to coronary artery disease (CAD) helps to enhance our understanding of the disease’s pathogenesis and facilitate the identification of novel therapeutic targets. Methods: Inflammation-related genes (IRGs) were downloaded from the Msigdb database. Differentially expressed genes (DEGs) were determined by comparing CAD group with the control group in the GSE113079 and GSE12288 datasets. Key module genes associated with CAD were identified through weighted gene co-expression network analysis (WGCNA). Differentially expressed IRGs (DE-IRGs) were established by intersecting the DEGs, key module genes, and IRGs. Feature genes were derived using machine learning techniques. Mendelian randomization (MR) analysis was conducted to explore the causal relationship between CAD and the identified feature genes. Subsequently, a logistic regression model and an alignment diagram model were developed to predict the incidence of CAD. Results: In the given datasets, a total of 92 DE-IRGs were identified. Furthermore, twelve feature genes were discerned utilizing four distinct machine learning algorithms. Notably, two pivotal genes, HIF1A (odds ratio (OR) = 1.031, P = 0.024) and TNFAIP3 (OR = 1.104, P = 0.007), exhibited a causal relationship with coronary artery disease (CAD). Additionally, logistic regression and alignment diagram models demonstrated their efficacy in predicting the incidence of CAD. Ultimately, TNFAIP3 and HIF1A were significantly associated with T-cell receptor and NOD-like receptor signaling pathways. Conclusion: The identification of TNFAIP3 and HIF1A as causal inflammatory biomarkers of CAD offers novel insights with significant clinical potential, which may provide valuable targets for the management and treatment of CAD.
- 1 March 2025
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 18, 3177-3200
Open AccessInflammatory Biomarkers in Coronary Artery Disease: Insights From Mendelian Randomization and Transcriptomics
Background: The identification of inflammatory genes linked to coronary artery disease (CAD) helps to enhance our understanding of the disease’s pathogenesis and facilitate the identification of novel therapeutic targets. Methods: Inflammation-related genes (IRGs) were downloaded from the Msigdb database. Differentially expressed genes (DEGs) were determined by comparing CAD group with the control group in the GSE113079 and GSE12288 datasets. Key module genes associated with CAD were identified through weighted gene co-expression network analysis (WGCNA). Differentially expressed IRGs (DE-IRGs) were established by intersecting the DEGs, key module genes, and IRGs. Feature genes were derived using machine learning techniques. Mendelian randomization (MR) analysis was conducted to explore the causal relationship between CAD and the identified feature genes. Subsequently, a logistic regression model and an alignment diagram model were developed to predict the incidence of CAD. Results: In the given datasets, a total of 92 DE-IRGs were identified. Furthermore, twelve feature genes were discerned utilizing four distinct machine learning algorithms. Notably, two pivotal genes, HIF1A (odds ratio (OR) = 1.031, P = 0.024) and TNFAIP3 (OR = 1.104, P = 0.007), exhibited a causal relationship with coronary artery disease (CAD). Additionally, logistic regression and alignment diagram models demonstrated their efficacy in predicting the incidence of CAD. Ultimately, TNFAIP3 and HIF1A were significantly associated with T-cell receptor and NOD-like receptor signaling pathways. Conclusion: The identification of TNFAIP3 and HIF1A as causal inflammatory biomarkers of CAD offers novel insights with significant clinical potential, which may provide valuable targets for the management and treatment of CAD.
- 29 July 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 139, 112789
TAX1BP1/A20 inhibited TLR2-NF-κB activation to induce tolerant expression of IL-6 in endothelial cells
- 29 July 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 139, 112789
TAX1BP1/A20 inhibited TLR2-NF-κB activation to induce tolerant expression of IL-6 in endothelial cells
- 1 December 2019
- Published by SAGE Publications in DNA and Cell Biology
- Vol. 38 (12) , 1557-1563
Anti-Inflammatory Activity of Adenosine 5′-Trisphosphate in Lipopolysaccharide-Stimulated Human Umbilical Vein Endothelial Cells Through Negative Regulation of Toll-Like Receptor MyD88 Signaling
Activation of TLR4-MyD88-NF-κB signaling by lipopolysaccharide (LPS) evokes a proinflammatory immune response, and plays a pivotal role in initiation and progression of atherosclerosis (AS). ATP (adenosine 5′-trisphosphate), a powerful extracellular signal transduction molecule, functions to regulate immune inflammatory responses depending on the type of P2 receptors and cell lines. In this study, we first performed RT-PCR to detect the mRNA expression of monocyte chemoattractant protein-1 (MCP-1), IL-8, and IL-1β induced by different concentrations of LPS in human umbilical vein endothelial cells (HUVECs). Protein level of TLR4 signaling including TLR4, myeloid differentiation factor (MyD88), and CD14 induced by LPS (1 μg/mL) at different times (0, 10, 30, 60, 120 min) was analyzed by Western blot. Then, RT-PCR was performed to detect the effect of different concentrations of ATP on mRNA expression of IL-1β and MCP-1 induced by LPS (1 μg/mL) and the TLR4 signaling pathway. Western blot was performed to detect the effect of low concentrations of ATP on phosphorylation of p65 induced by 1 μg/mL LPS. Finally, we used P2Y receptor blocker Suramin to verify whether the role of ATP on LPS-induced inflammatory cytokine expression was through P2Y receptors. The results showed that LPS upregulated the expression of MCP-1, IL-8, and IL-1β in a dose-dependent manner accompanied by the activation of TLR4-MyD88 signaling in HUVECs. Only low concentration ATP (1, 10 μM) inhibited LPS-induced mRNA expression of IL-1β and MCP-1. ATP at low concentrations also downregulated the mRNA expression of TLR4, CD14, and MyD88 and inhibited LPS-induced phosphorylation of p65. Furthermore, Suramin, a nonspecific P2Y receptor antagonist, did not attenuate the inhibition of ATP on LPS-induced IL-1β and MCP-1 expression. Taking this together, low concentration ATP inhibited LPS-induced inflammation in HUVECs by negatively regulating TLR4-MyD88 signaling, and P2Y receptors were not involved in this process, which might provide new ideas for prevention and treatment of inflammatory diseases such as AS.
- 1 December 2019
- Published by SAGE Publications in DNA and Cell Biology
- Vol. 38 (12) , 1557-1563
Anti-Inflammatory Activity of Adenosine 5′-Trisphosphate in Lipopolysaccharide-Stimulated Human Umbilical Vein Endothelial Cells Through Negative Regulation of Toll-Like Receptor MyD88 Signaling
Activation of TLR4-MyD88-NF-κB signaling by lipopolysaccharide (LPS) evokes a proinflammatory immune response, and plays a pivotal role in initiation and progression of atherosclerosis (AS). ATP (adenosine 5′-trisphosphate), a powerful extracellular signal transduction molecule, functions to regulate immune inflammatory responses depending on the type of P2 receptors and cell lines. In this study, we first performed RT-PCR to detect the mRNA expression of monocyte chemoattractant protein-1 (MCP-1), IL-8, and IL-1β induced by different concentrations of LPS in human umbilical vein endothelial cells (HUVECs). Protein level of TLR4 signaling including TLR4, myeloid differentiation factor (MyD88), and CD14 induced by LPS (1 μg/mL) at different times (0, 10, 30, 60, 120 min) was analyzed by Western blot. Then, RT-PCR was performed to detect the effect of different concentrations of ATP on mRNA expression of IL-1β and MCP-1 induced by LPS (1 μg/mL) and the TLR4 signaling pathway. Western blot was performed to detect the effect of low concentrations of ATP on phosphorylation of p65 induced by 1 μg/mL LPS. Finally, we used P2Y receptor blocker Suramin to verify whether the role of ATP on LPS-induced inflammatory cytokine expression was through P2Y receptors. The results showed that LPS upregulated the expression of MCP-1, IL-8, and IL-1β in a dose-dependent manner accompanied by the activation of TLR4-MyD88 signaling in HUVECs. Only low concentration ATP (1, 10 μM) inhibited LPS-induced mRNA expression of IL-1β and MCP-1. ATP at low concentrations also downregulated the mRNA expression of TLR4, CD14, and MyD88 and inhibited LPS-induced phosphorylation of p65. Furthermore, Suramin, a nonspecific P2Y receptor antagonist, did not attenuate the inhibition of ATP on LPS-induced IL-1β and MCP-1 expression. Taking this together, low concentration ATP inhibited LPS-induced inflammation in HUVECs by negatively regulating TLR4-MyD88 signaling, and P2Y receptors were not involved in this process, which might provide new ideas for prevention and treatment of inflammatory diseases such as AS.
- 24 August 2018
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 120 (2) , 1783-1793
Adenosine diphosphate–sensitive P2Y11 receptor inhibits endothelial cell proliferation by induction of cell cycle arrest in the S phase and induces the expression of inflammatory mediators
Extracellular adenosine diphosphate (ADP) mediates a wide range of physiological effects as an extracellular signaling molecule, including platelet aggregation, vascular tone, cell proliferation, and apoptosis by interacting with plasma membrane P2 receptors. However, the effect of ADP on cell proliferation was contradictory. In this study, we found that ADP significantly inhibited cell proliferation of human umbilical vein endothelial cells at high concentrations (50 to 100 µM). Treatment with ADP did not induce cell apoptosis but instead induced cell cycle arrest in the S phase, which may be partly due to the downregulation of cyclin B1. The inhibition of cell proliferation was blocked by suramin, a nonspecific antagonist of the P2 receptors, and high concentrations of ADP significantly upregulated the messenger RNA (mRNA) and protein expression of P2Y11 in endothelial cells. Moreover, the downregulation of P2Y11 by RNA interference reversed the inhibition of cell proliferation. In addition, ADP (100 µM) can induce the formation of cytosolic autophagy in endothelial cells and a rapid phosphorylation of extracellular signal regulated kinase (ERK) 1/2, which is a canonical signal molecule downstream of P2Y receptors, accompanied by a mRNA expression of proinflammatory cytokines such as intercellular adhesion molecule 1 and vascular cell adhesion molecule 1. Taken together, our study excludes a mechanism for extracellular ADP impairing endothelial cells proliferation via P2Y11 receptor by downregulating cyclin B1 and arresting cell cycle at the S phase, besides, ADP induces cell autophagy and mRNA expression of inflammatory cytokines, whether it is mediated by Erk signaling pathways needs further studies to confirm.
- 24 August 2018
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 120 (2) , 1783-1793
Adenosine diphosphate–sensitive P2Y11 receptor inhibits endothelial cell proliferation by induction of cell cycle arrest in the S phase and induces the expression of inflammatory mediators
Extracellular adenosine diphosphate (ADP) mediates a wide range of physiological effects as an extracellular signaling molecule, including platelet aggregation, vascular tone, cell proliferation, and apoptosis by interacting with plasma membrane P2 receptors. However, the effect of ADP on cell proliferation was contradictory. In this study, we found that ADP significantly inhibited cell proliferation of human umbilical vein endothelial cells at high concentrations (50 to 100 µM). Treatment with ADP did not induce cell apoptosis but instead induced cell cycle arrest in the S phase, which may be partly due to the downregulation of cyclin B1. The inhibition of cell proliferation was blocked by suramin, a nonspecific antagonist of the P2 receptors, and high concentrations of ADP significantly upregulated the messenger RNA (mRNA) and protein expression of P2Y11 in endothelial cells. Moreover, the downregulation of P2Y11 by RNA interference reversed the inhibition of cell proliferation. In addition, ADP (100 µM) can induce the formation of cytosolic autophagy in endothelial cells and a rapid phosphorylation of extracellular signal regulated kinase (ERK) 1/2, which is a canonical signal molecule downstream of P2Y receptors, accompanied by a mRNA expression of proinflammatory cytokines such as intercellular adhesion molecule 1 and vascular cell adhesion molecule 1. Taken together, our study excludes a mechanism for extracellular ADP impairing endothelial cells proliferation via P2Y11 receptor by downregulating cyclin B1 and arresting cell cycle at the S phase, besides, ADP induces cell autophagy and mRNA expression of inflammatory cytokines, whether it is mediated by Erk signaling pathways needs further studies to confirm.
- 1 December 2011
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 58 (6) , 617-625
The Effect of Endothelial Progenitor Cells on Angiotensin II–induced Proliferation of Cultured Rat Vascular Smooth Muscle Cells
Previous studies have demonstrated that endothelial progenitor cells (EPCs) could delay the progress of vascular remodeling in blood vessel–proliferating diseases. The proliferation of vascular smooth muscle cells (VSMCs) is a pivotal factor in cardiovascular diseases. In this study, we investigated whether EPCs could inhibit the Angiotensin II (Ang II)–induced proliferation of VSMCs. The effect of early EPC-conditioned medium (E-EPC-CM), late EPCs-CM (L-EPC-CM), and HUVEC-CM on Ang II–induced proliferation of VSMCs was assessed by BrdU incorporation, total protein content, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays, and flow cytometry. Reverse transcriptase–polymerase chain reaction and Western blot were performed to analyze the effect of different CMs on Ang II–induced phosphorylations of ERK, JNK, p38, and NF-κB subunit p65 and the expressions of c-myc and c-fos. E-EPC-CM, L-EPC-CM, and HUVEC-CM significantly inhibited the Ang II–induced DNA synthesis, total protein expression, cell survival, and cell cycle progress of VSMCs. Furthermore, E-EPC-CM significantly inhibited the Ang II–induced phosphorylation of ERK, JNK, p38, and p65 (nuclear translocation of p65) and the expressions of c-myc and c-fos. Taken together, these data suggested that EPCs may delay the progress of vascular remodeling in blood vessel–proliferating diseases by inhibiting Ang II–induced proliferation of VSMCs through inactivating MAPKs and NF-κB signaling pathways and by reducing the expressions of c-myc and c-fos.
- 1 December 2011
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 58 (6) , 617-625
The Effect of Endothelial Progenitor Cells on Angiotensin II–induced Proliferation of Cultured Rat Vascular Smooth Muscle Cells
Previous studies have demonstrated that endothelial progenitor cells (EPCs) could delay the progress of vascular remodeling in blood vessel–proliferating diseases. The proliferation of vascular smooth muscle cells (VSMCs) is a pivotal factor in cardiovascular diseases. In this study, we investigated whether EPCs could inhibit the Angiotensin II (Ang II)–induced proliferation of VSMCs. The effect of early EPC-conditioned medium (E-EPC-CM), late EPCs-CM (L-EPC-CM), and HUVEC-CM on Ang II–induced proliferation of VSMCs was assessed by BrdU incorporation, total protein content, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays, and flow cytometry. Reverse transcriptase–polymerase chain reaction and Western blot were performed to analyze the effect of different CMs on Ang II–induced phosphorylations of ERK, JNK, p38, and NF-κB subunit p65 and the expressions of c-myc and c-fos. E-EPC-CM, L-EPC-CM, and HUVEC-CM significantly inhibited the Ang II–induced DNA synthesis, total protein expression, cell survival, and cell cycle progress of VSMCs. Furthermore, E-EPC-CM significantly inhibited the Ang II–induced phosphorylation of ERK, JNK, p38, and p65 (nuclear translocation of p65) and the expressions of c-myc and c-fos. Taken together, these data suggested that EPCs may delay the progress of vascular remodeling in blood vessel–proliferating diseases by inhibiting Ang II–induced proliferation of VSMCs through inactivating MAPKs and NF-κB signaling pathways and by reducing the expressions of c-myc and c-fos.
- 21 May 2011
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 355 (1-2) , 99-108
Calcitonin gene-related peptide released from endothelial progenitor cells inhibits the proliferation of rat vascular smooth muscle cells induced by angiotensin II
We have recently demonstrated that endothelial progenitor cells (EPCs) inhibit AngII-induced proliferation of vascular smooth muscle cells (VSMCs) by inactivating MAPKs and NF-κB signaling pathway and reducing expression of oncogene c-myc and c-fos. The inhibitory effect of EPCs on VSMCs is associated with paracrine mechanism. However, the potential mechanism of EPCs on the regulation of AngII-induced proliferation of VSMCs was unknown. Calcitonin gene-related peptide (CGRP) could inhibit AngII-induced proliferation and transformation of VSMCs. However, it has not been known whether CGRP released from EPCs is a potential regulator in regulation of AngII-induced proliferation of VSMCs. Early endothelial progenitor cell-conditioned medium(E-EPC-CM) was pre-incubated with functional blocking antibodies against CGRP for 1 h or VSMCs was preteated with CGRP837(CGRP receptor antagonist) for 1 h before VSMCs were pretreated with CM for 30 min. DNA synthesis ability, total protein levels, cell survival, signal transduction, and expressions of c-myc and c-fos of VSMCs induced by AngII (10−6mol/l) were detected to assess the role of CGRP in AngII-induced proliferation of VSMCs. E-EPC-CM could significantly inhibit AngII-induced DNA synthesis ability, total protein levels, cell survival, phosphorylation of ERK, JNK, p38, p65, and expressions of c-myc and c-fos compared with the control group(P < 0.05). However, Pretreatment with anti-CGRP antibody and CGRP837 could significantly weaken the inhibitory effect of E-EPC-CM on proliferation of VSMCs induced by AngII (P < 0.05). EPCs exert anti-proliferative effects on VSMCs mediated by the release of CGRP.
- 21 May 2011
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 355 (1-2) , 99-108
Calcitonin gene-related peptide released from endothelial progenitor cells inhibits the proliferation of rat vascular smooth muscle cells induced by angiotensin II
We have recently demonstrated that endothelial progenitor cells (EPCs) inhibit AngII-induced proliferation of vascular smooth muscle cells (VSMCs) by inactivating MAPKs and NF-κB signaling pathway and reducing expression of oncogene c-myc and c-fos. The inhibitory effect of EPCs on VSMCs is associated with paracrine mechanism. However, the potential mechanism of EPCs on the regulation of AngII-induced proliferation of VSMCs was unknown. Calcitonin gene-related peptide (CGRP) could inhibit AngII-induced proliferation and transformation of VSMCs. However, it has not been known whether CGRP released from EPCs is a potential regulator in regulation of AngII-induced proliferation of VSMCs. Early endothelial progenitor cell-conditioned medium(E-EPC-CM) was pre-incubated with functional blocking antibodies against CGRP for 1 h or VSMCs was preteated with CGRP837(CGRP receptor antagonist) for 1 h before VSMCs were pretreated with CM for 30 min. DNA synthesis ability, total protein levels, cell survival, signal transduction, and expressions of c-myc and c-fos of VSMCs induced by AngII (10−6mol/l) were detected to assess the role of CGRP in AngII-induced proliferation of VSMCs. E-EPC-CM could significantly inhibit AngII-induced DNA synthesis ability, total protein levels, cell survival, phosphorylation of ERK, JNK, p38, p65, and expressions of c-myc and c-fos compared with the control group(P < 0.05). However, Pretreatment with anti-CGRP antibody and CGRP837 could significantly weaken the inhibitory effect of E-EPC-CM on proliferation of VSMCs induced by AngII (P < 0.05). EPCs exert anti-proliferative effects on VSMCs mediated by the release of CGRP.